AI Terminal
aap Implantate AG
Regulatory Filings • Jun 30, 2017
10_rns_2017-06-30_afe73c98-c527-4cbd-80c2-2cbc1f39eb91.html
Regulatory Filings
Open in ViewerOpens in native device viewer
News Details
Corporate | 30 June 2017 16:39
aap Implantate AG: Update regarding antibacterial silver coating technology – Preparations for clinical human study under way
DGAP-News: aap Implantate AG / Key word(s): Study/Regulatory Admission
30.06.2017 / 16:39
The issuer is solely responsible for the content of this announcement.
aap Implantate AG (“ aap “) provides an update on the recent developments regarding the aimed CE and FDA approval for its antibacterial silver coating technology. Based on the previous talks with the involved authorities as well as the internal development progress, aap will initiate various further preparations for the implementation of a clinical human study in the second half of 2017. In addition, the coordination of the design and the extent of the human study with the competent authorities will be continued. The company will publish further details about the study at the beginning of 2018.
The internationally IP-protected silver coating technology developed by aap protects the surface of implants from bacterial colonisation. The technology thus addresses one of the critical and not yet adequately solved problems of surgery: the reduction of infection risks when using metal implants. aap’ s silver coating technology has several unique selling propositions such as a high coating stability as well as a good biocompatibility and effectiveness. These properties have been demonstrated in a number of different test series. Furthermore, it is a cost-effective coating technology that is scalable to higher production volumes with reasonable expense as investments for the required coating machinery are relatively low.
As a platform technology aap’ s silver coating technology has a wide range of applications and can be used not only in orthopaedics but also in different further areas such as cardiology, dentistry or for medical instruments.
Along with preparing for the clinical human study aap is currently in talks with various global companies on potential joint development projects in the field of silver coating technology.
_______________________________________________________________________________________
aap Implantate AG (ISIN DE0005066609) – Prime Standard/Regulated Market – All German stock markets –
About aap Implantate AG
aap Implantate AG is a globally operating medical device company headquartered in Berlin, Germany. The company develops, manufactures and markets trauma products for orthopaedics. The IP protected portfolio includes besides the innovative anatomical plating system LOQTEQ(R) and trauma complementary biomaterials a wide range of cannulated screws as well as standard plates and screws. Furthermore, aap Implantate AG has an innovation pipeline with promising development projects as the antibacterial silver coating technology and magnesium based implants. These technologies address critical problems in surgery that haven’t yet been resolved adequately. In German-speaking Europe aap Implantate AG directly sells its products to hospitals, buying syndicates and hospital groups while it uses a broad network of distributors in more than 25 countries at the international level. aap Implantate AG’s stock is listed in the Prime Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit www.aap.de, or download the Company’s investor relations app from the Apple’s App Store or Google Play.
Forward-looking statement
This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap ‘s public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.
Contact:
aap Implantate AG; Fabian Franke; Investor Relations; Lorenzweg 5; D-12099 Berlin Tel.: ++49/30/750 19 – 134; Fax.: ++49/30/750 19 – 290; [email protected]
30.06.2017 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
| Language: | English |
| Company: | aap Implantate AG |
| Lorenzweg 5 | |
| 12099 Berlin | |
| Germany | |
| Phone: | +49 (0) 30 75 01 90 |
| Fax: | +49 (0) 30 75 01 91 11 |
| E-mail: | [email protected] |
| Internet: | www.aap.de |
| ISIN: | DE0005066609 |
| WKN: | 506660 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| End of News | DGAP News Service |